http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2638579-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9a95d0c63b9b3f2bc8e8d6b45fbe7789 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-77 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-71 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate | 2009-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b832f6b5e531859ab5cad2697ab1043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97375d6094bca0a15721f7ee1540bdfe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9a73c7bac04ecd8d96812437f36d1a3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f03f115d268f196553c8e923c4b1ffbb |
| publicationDate | 2017-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2638579-T3 |
| titleOfInvention | Compositions of recombinant antibodies against epidermal growth factor receptor |
| abstract | An antibody composition for use in treating cancer in a subject who has undergone a prior treatment regimen involving an anti-human EGFR antibody, said antibody composition comprising a first molecule of anti-human EGFR antibody and a second anti-human EGFR antibody molecule other than the first molecule, a) wherein the first anti-human EGFR antibody molecule is selected from the group consisting of: i) an antibody whose light chain comprises amino acids 3-216 of SEQ ID NO: 72, and whose heavy chain comprises amino acids 3-124 of SEQ ID NO: 40 and the amino acid sequence of SEQ ID NO: 91; ii) an antibody whose light chain comprises amino acids 3-109 of SEQ ID NO: 72 and whose heavy chain comprises amino acids 3-124 of SEQ ID NO: 40; and iii) an antibody having the light chain CDR1, CDR2 and CDR3 in SEQ ID NO: 72 and the heavy chain CDR1, CDR2 and CDR3 in SEQ ID NO: 40; and b) wherein the second anti-human EGFR antibody molecule is selected from the group consisting of: i) an antibody whose light chain comprises amino acids 3-221 of SEQ ID NO: 73, and whose heavy chain comprises amino acids 3 -120 of SEQ ID NO: 41 and the amino acid sequence of SEQ ID NO: 91; ii) an antibody whose light chain comprises amino acids 3-114 of SEQ ID NO: 73 and whose heavy chain comprises amino acids 3-120 of SEQ ID NO: 41; and iii) an antibody having the light chain CDR1, CDR2 and CDR3 in SEQ ID NO: 73 and the heavy chain CDR1, CDR2 and CDR3 in SEQ ID NO: 41. |
| priorityDate | 2008-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 331.